Healthcare has been an increasingly important priority in many countries as governments seek to rein in burgeoning healthcare costs. One disease that is in the spotlight is diabetes, a chronic illness characterised by high levels of blood glucose which, over time, leads to severe damage to the heart, blood vessels, eyes, and kidneys. Back in 2000, 151 million aged 20 to 79 were diagnosed with this disease but this number has since more than tripled to 537 million in 2021. DexCom (NASDAQ: DXCM) helps people suffering from Type II Diabetes to control and monitor their blood glucose levels through its innovative continuous glucose monitoring (CGM) systems. This healthcare company’s share price, however, saw a sharp 41% plunge recently to hit its 52-week low of US$62.34. The fall is the sharpest-ever for the stock since the company went public in 2005 and year-to-date, the stock is down around 43.4%. Should growth investors see this as a great opportunity to accumulate the stock?...